Movano Health reports Q3 operating loss $7.4M, ships 339 Evie Rings, reverse split completed

Corvex, Inc.

2024-Q3 EPS reported -$3.33 revenue$902,000

Operating loss of $7.4M in Q3 2024, improved from $9.1M loss in Q3 2023.
Cash and equivalents at Sept 30, 2024: $11.3M.
1-for-15 reverse stock split executed Oct 29; Nasdaq bid price compliance regained Nov 12.
EvieMED 510(k) review in final stage; complete response submitted late Oct for medical features.
Entered agreement phase for Q1 2025 pilot program with large healthcare company using EvieMED.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.